370 related articles for article (PubMed ID: 10897121)
1. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
[TBL] [Abstract][Full Text] [Related]
2. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
[TBL] [Abstract][Full Text] [Related]
3. The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patients.
Gameiro P; Vieira S; Carrara P; Silva AL; Diamond J; Botelho de Sousa A; Mehta AB; Prentice HG; Guimarães JE; Hoffbrand AV; Foroni L; Parreira A
Haematologica; 2001 Jun; 86(6):577-85. PubMed ID: 11418366
[TBL] [Abstract][Full Text] [Related]
4. Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely.
Martinelli G; Rondoni M; Buonamici S; Ottaviani E; Piccaluga PP; Malagola M; Baccarani M
Haematologica; 2004 Apr; 89(4):495-7. PubMed ID: 15075086
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
[TBL] [Abstract][Full Text] [Related]
6. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
[TBL] [Abstract][Full Text] [Related]
8. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.
Laczika K; Mitterbauer G; Mitterbauer M; Knöbl P; Schwarzinger I; Greinix HT; Rabitsch W; Fonatsch C; Mannhalter C; Lechner K; Jaeger U
Leuk Lymphoma; 2001; 42(5):923-31. PubMed ID: 11697647
[TBL] [Abstract][Full Text] [Related]
9. [Detection of CBF beta-MYH11 fusion transcript and inv(16)(p13;q22) in acute myelomonocytic leukemia(M4) by RT-PCR and FISH].
He K; Gu B; Cao Q
Zhonghua Xue Ye Xue Za Zhi; 1998 Jan; 19(1):23-6. PubMed ID: 10921098
[TBL] [Abstract][Full Text] [Related]
10. Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): a single-institution study of 224 Japanese AML patients.
Monma F; Nishii K; Shiga J; Sugahara H; Lorenzo F; Watanabe Y; Kawakami K; Hosokai N; Yamamori S; Katayama N; Shiku H
Leuk Res; 2007 Apr; 31(4):471-6. PubMed ID: 17052753
[TBL] [Abstract][Full Text] [Related]
11. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.
Krauter J; Hoellge W; Wattjes MP; Nagel S; Heidenreich O; Bunjes D; Ganser A; Heil G
Genes Chromosomes Cancer; 2001 Apr; 30(4):342-8. PubMed ID: 11241787
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
Corbacioglu A; Scholl C; Schlenk RF; Eiwen K; Du J; Bullinger L; Fröhling S; Reimer P; Rummel M; Derigs HG; Nachbaur D; Krauter J; Ganser A; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(23):3724-9. PubMed ID: 20625124
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
Perea G; Lasa A; Aventín A; Domingo A; Villamor N; Queipo de Llano MP; Llorente A; Juncà J; Palacios C; Fernández C; Gallart M; Font L; Tormo M; Florensa L; Bargay J; Martí JM; Vivancos P; Torres P; Berlanga JJ; Badell I; Brunet S; Sierra J; Nomdedéu JF;
Leukemia; 2006 Jan; 20(1):87-94. PubMed ID: 16281071
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and follow-up of acute promyelocytic leukemia by detection of PML-RAR alpha gene rearrangement.
Gau JP; Young JH; Lin TH; Yang YS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):175-81. PubMed ID: 10746412
[TBL] [Abstract][Full Text] [Related]
15. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
Boeckx N; Willemse MJ; Szczepanski T; van der Velden VH; Langerak AW; Vandekerckhove P; van Dongen JJ
Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
[TBL] [Abstract][Full Text] [Related]
16. Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFbeta/MYH11 transcript.
Martinelli G; Ottaviani E; Testoni N; Montefusco V; Pastano R; Tura S
Haematologica; 2000 May; 85(5):552-5. PubMed ID: 10800179
[No Abstract] [Full Text] [Related]
17. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
18. Assessment of residual disease in acute leukemia by means of polymerase chain reaction.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Pérez-Romano B; Ruiz-Argüelles A; Ramírez-Cisneros FJ; López-Martínez B; López-Tapia JD; Rivadeneyra-Espinoza L
Rev Invest Clin; 2000; 52(2):118-24. PubMed ID: 10846434
[TBL] [Abstract][Full Text] [Related]
19. High concordance of karyotype analysis and RT-PCR for CBF beta/MYH11 in unselected patients with acute myeloid leukemia. A single center study.
Mitterbauer M; Laczika K; Novak M; Mitterbauer G; Hilgarth B; Pirc-Danoewinata H; Schwarzinger I; Haas OA; Fonatsch C; Lechner K; Jaeger U
Am J Clin Pathol; 2000 Mar; 113(3):406-10. PubMed ID: 10705822
[TBL] [Abstract][Full Text] [Related]
20. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
